
|Articles|October 1, 2012
Various factors dictate which neuromodulator to use, and when
As research and clinical experience continue to underscore differences between the three neuromodulators available in the United States, picking a product for a given clinical situation rests largely upon individual preference, according to Joel L. Cohen, M.D., who spoke earlier this year at MauiDerm 2012: Advances in Cosmetic and Medical Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
2
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
3
Kyowa Kirin Takes Full Control of Rocatinlimab Program
4
Dermatology Times January 2026 Recap
5











